ARIKAYCE
amikacin liposome inhalation suspension- Nontuberculous Mycobacterial Lung Infection
- Mycobacterium avium Complex Lung Disease
- MAC Lung Disease
Most recent annual filing: 2026-02-19
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Liposomal drug delivery technology enabling inhaled delivery of amikacin directly to the lungs via macrophage uptake, limiting systemic exposure; used in ARIKAYCE for MAC lung disease
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.